The abstract is read at the publisher; the summary is JClub's.
89Zr-CB307 PET shows selective accumulation in PSMA-positive metastatic castration-resistant prostate cancer lesions, with liver uptake (SUVmean 13.06 ± 2.68 at day 7) and no spleen or marrow uptake.
- Why it matters: PSMA-targeted imaging and therapy can be limited by off-target distribution and uncertain tumor penetration, so biodistribution data for a tri-specific Humabody is needed.
- What they did: In five patients with PSMA-positive mCRPC, baseline 18F-PSMA PET preceded 89Zr-CB307 (37 MBq/5 mg) with escalating unlabeled CB307 up to 100 mg; SUVmax was measured across time points.
- The result: Across all 18F-PSMA-positive lesions, geometric mean SUVmax increased from 3.53 (day 2) to 4.12 (day 7) at the highest protein dose, and biopsies plus autoradiography supported lesion-associated radioactivity.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.